Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	744.70M
Revenue (ttm)	250.29M
Net Income (ttm)	125.00M
Shares Out	16.02M
EPS (ttm)	7.61
PE Ratio	6.11
Forward PE	7.55
Dividend	1.91 (4.17%)
Ex-Dividend Date	n/a

Volume	2,942
Average Volume	24,583
Open	46.60
Previous Close	46.50
Day's Range	46.10 - 46.85
52-Week Range	44.95 - 80.60
Beta	1.38
RSI	33.23
Earnings Date	Jul 23, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR